Drug Science (UK) has selected an African company as its supplier for its medical cannabis-focused clinical research initiative, Project Twenty21. The business in question: MG Health Limited, from the Kingdom of Lesotho.

According to the companies, Project Twenty21will target 20,000 U.K.-based patients suffering from chronic pain, anxiety disorder, epilepsy, multiple sclerosis, Post Traumatic Stress Disorder; substance use disorder and Tourette’s Syndrome. Researchers will look into the potential benefits of medical cannabis for the treatment of said conditions.

Francois Ferreira, COO of MG Health told Benzinga he thinks Project Twenty21 is a “bold initiative.” He noted his company sees this study as “a significant step toward collecting data from a large group of patients.

– Read the entire article at Benzinga.